2024-01-04 09:13:00 |
First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial |
0 |
https://app.sharelinktechnologies.com/announcement/asx/0681f63cab07a4c3339c60fc213712bf |
|
2024-01-08 08:22:00 |
Immutep Corporate Presentation |
0 |
https://app.sharelinktechnologies.com/announcement/asx/8eab8e68671a37661d3c8cedf1940b80 |
|
2024-01-15 17:03:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/dddc7997dcc4a85236bde28e098ab7fa |
Change in substantial holding
|
2024-01-30 08:32:00 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/f974b1158e6e9fe43fab9a64b21cf036 |
Commitments Test Entity - Second Quarter Report
Commitments Test Entity - Second Quarter Activity Report
|
2024-01-31 19:31:00 |
Notification regarding unquoted securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/49b6c543ff2139acc7d4c3e029ab5a84 |
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
|
2024-02-14 09:12:00 |
Appointment of Non-Executive Director |
0 |
https://app.sharelinktechnologies.com/announcement/asx/c5bf709600c2755d526d0876d9d4cced |
Director Appointment/Resignation
|
2024-02-14 10:20:00 |
Appendix 3X - Anne Anderson |
0 |
https://app.sharelinktechnologies.com/announcement/asx/b88c65f565f3f9ed4d4bbde429e16571 |
Initial Director's Interest Notice
|
2024-02-14 13:05:00 |
Ceasing to be a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/8c8900ee77c1a7169f41d4ad4edf0845 |
Ceasing to be a substantial holder
|
2024-02-15 16:45:00 |
Becoming a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/76ab17c47eabb7c014e14b4f46740c48 |
Becoming a substantial holder
|
2024-02-20 16:46:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/08a43b9d275c2c087e56e061fead178c |
Change in substantial holding
|
2024-02-21 16:55:00 |
Immutep Investor Update |
0 |
https://app.sharelinktechnologies.com/announcement/asx/1dbd4ec3cc065acdb862bfcfcfeb230e |
|
2024-02-22 18:14:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/a6b56aa2a36b5858d438262606935a3f |
Change in substantial holding
|
2024-02-26 16:47:00 |
Becoming a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/0e15d7a4803eb2318752c4ec8deb3e5e |
Becoming a substantial holder
|
2024-02-28 09:39:00 |
Half Yearly Report and Accounts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/923355c17b6516dd53465405abacbd63 |
Half Year Directors' Statement
Half Year Directors' Report
|
2024-03-05 12:34:00 |
First Clinical Data announced from 90mg Dosing of Efti |
1 |
https://app.sharelinktechnologies.com/announcement/asx/e7eb8029b775cc6ef3029596453570a0 |
|
2024-03-08 16:27:00 |
Ceasing to be a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/5072a2741ccc5e921edc61a6523422b6 |
Ceasing to be a substantial holder
|
2024-04-11 18:30:00 |
Ceasing to be a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/4a319c100c2afa915652dcdaae237244 |
Ceasing to be a substantial holder
|
2024-04-17 09:10:00 |
Positive Feedback received from Spanish Medicines Agency |
0 |
https://app.sharelinktechnologies.com/announcement/asx/d43894001dafa767ff0f66e980d8cca2 |
|
2024-04-18 09:36:00 |
CHDR to conduct first-in-human phase 1 trial of IMP761 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/a98578c19ebb71f188e1e45a50925906 |
|
2024-04-24 08:40:00 |
Positive preliminary topline results from TACTI-003 Cohort B |
1 |
https://app.sharelinktechnologies.com/announcement/asx/b2451fe39828d6a3bc21477964b57aff |
|
2024-04-29 08:18:00 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/35d064011d471f1cca85165ef4aaee1a |
Commitments Test Entity - Third Quarter Report
Commitments Test Entity - Third Quarter Activity Report
|
2024-05-02 09:29:00 |
Positive initial data in phase 2 Soft Tissue Sarcoma trial |
1 |
https://app.sharelinktechnologies.com/announcement/asx/24f49f8204f4760123e9087c622c4511 |
|
2024-05-15 18:01:00 |
AIPAC-003 safety lead-in data presented at ESMO Breast 2024 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/9eb3278d9e3ac507acecc898dd73301e |
|
2024-06-03 08:51:00 |
Trading Halt |
1 |
https://app.sharelinktechnologies.com/announcement/asx/43f1ca7e5e47afbb3884635083c1902e |
|
2024-06-03 09:14:00 |
A$100 million fully underwritten equity raising |
1 |
https://app.sharelinktechnologies.com/announcement/asx/26136f6e9e3d0db0120f09828ba9abb9 |
|
2024-06-03 09:19:00 |
Immutep Capital Raising Presentation |
1 |
https://app.sharelinktechnologies.com/announcement/asx/799ffde1268524e73b1f875e31347238 |
|
2024-06-03 09:28:00 |
Proposed issue of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/95995a9bf07a9771fcdb4c8f820c1910 |
|
2024-06-03 09:41:00 |
Immutep announces Ph 3 clinical trial collaboration with MSD |
1 |
https://app.sharelinktechnologies.com/announcement/asx/fe0d6f7ca0f0591ba6df1946be184838 |
|
2024-06-03 10:00:00 |
Cleansing Notice |
0 |
https://app.sharelinktechnologies.com/announcement/asx/694b4b2625b95c2b2fd0acde10dec370 |
|
2024-06-05 09:11:00 |
Immutep completes institutional pro-rata offer & placement |
1 |
https://app.sharelinktechnologies.com/announcement/asx/3ff9d50f9b9307e6bf606cccefcaf8f2 |
|
2024-06-07 12:53:00 |
Immutep retail entitlement offer booklet |
0 |
https://app.sharelinktechnologies.com/announcement/asx/088affa7bb319d3fcff0726c9469c5ef |
|
2024-06-07 13:02:00 |
Immutep letter to ineligible shareholders |
0 |
https://app.sharelinktechnologies.com/announcement/asx/ee732df5d1565b5a4475b6225170d9a3 |
|
2024-06-12 09:30:00 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/818307d8f0d9ff4155f9c5be6b140e28 |
Appendix 2A (Application for Quotation of Securities
|
2024-06-12 10:10:00 |
Cleansing Notice |
0 |
https://app.sharelinktechnologies.com/announcement/asx/94830e3d827e21f8c3e4c39f6fa048b1 |
|
2024-06-14 08:19:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9cc703c46fe703f60d717ab0ac181af2 |
Change in substantial holding
|
2024-06-14 16:49:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/99ce5e7eff1927f5e3bdc9e29739693a |
Change in substantial holding
|
2024-06-18 12:16:00 |
Change in substantial holding from IFL |
0 |
https://app.sharelinktechnologies.com/announcement/asx/1502c85a799a8961d3f3b9ccf8068cdd |
Change in substantial holding
|
2024-06-24 13:53:00 |
Immutep completes underwritten retail entitlement offer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/9babeb08b25b0f91ba73adb9a30b2b22 |
|
2024-06-25 08:16:00 |
Immutep signs agreement for anti-LAG-3 small molecules |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6d9a36a3f6f55e5f4bc8e20adab8ca98 |
|
2024-06-25 08:59:00 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/b1de55ba56e3ebf02d8f12ced083102e |
Appendix 2A (Application for Quotation of Securities
|
2024-06-27 08:09:00 |
Positive topline results from ph2b in head & neck cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/01c5467c4a7bfb7ff699b32dd8adcd34 |
|
2024-06-27 08:31:00 |
Webcast slides for new Efti clinical data in 1st line HNSCC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/b235b06f7415ed3bc29fec34729a0282 |
|
2024-07-03 08:33:00 |
Details for Immutep Webcast & ESMO Virtual Plenary Session |
0 |
https://app.sharelinktechnologies.com/announcement/asx/85d22153acabcc162a340f52533bea2a |
|
2024-07-04 08:16:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/963ab987dafaac2b364ba94cb2aa75ca |
Change in substantial holding
|
2024-07-12 08:26:00 |
Webcast to discuss data presented at ESMO Plenary Session |
1 |
https://app.sharelinktechnologies.com/announcement/asx/95e5ec28b393fecd37252210d1457b4b |
|
2024-07-12 08:26:00 |
Positive results in TACTI-003 for 1L HNSCC cohort B patients |
1 |
https://app.sharelinktechnologies.com/announcement/asx/33fe812d78c0112b1d0aaf1dfc7178ee |
|
2024-07-12 15:51:00 |
Becoming a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/30fa848918c13be9b89893ce8a1ff451 |
Becoming a substantial holder
|
2024-07-17 08:48:00 |
Regulatory Clearance received for Phase 1 trial of IMP761 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/9e31eb4c7a341fe1f7927a832d68b447 |
|
2024-07-22 08:12:00 |
Successful Meeting with FDA on Phase III Design in NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/51086c5abb8fdd3bbf98f9457a22db26 |
|
2024-07-26 16:43:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/a849231eebbaad415c2ef36c7ff64bbb |
Change in substantial holding
|
2024-07-31 09:28:00 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/406bc9ab12b0345399ba44d1c2e9b18b |
Commitments Test Entity - Fourth Quarter Report
Commitments Test Entity - Fourth Quarter Activity Report
|
2024-08-07 09:12:00 |
Immutep to Participate in Upcoming Investor Conferences |
0 |
https://app.sharelinktechnologies.com/announcement/asx/3b13202a9df85eddd6e654549620dee1 |
|
2024-08-14 08:19:00 |
First Participant Dosed in Phase I Study of IMP761 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/ba56fa85a413ef34be18be0caf36c07b |
|
2024-08-20 09:50:00 |
TACTI-003 data selected for oral presentation at ESMO 2024 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/a1f1e97d7768b2df3b5095136a27e247 |
Company Administration - Other
|
2024-08-21 09:26:00 |
Immutep Corporate Presentation |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6b7f69925dc47162548e2e3090f39b97 |
|
2024-08-30 09:55:00 |
Appendix 4E & 2024 Full Year Statutory Accounts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/c1a70b0380c9baa0c19e7307bc018f79 |
Full Year Directors' Statement
Full Year Directors' Report
|
2024-09-06 17:10:00 |
S&P DJI Announces September 2024 Quarterly Rebalance |
1 |
https://app.sharelinktechnologies.com/announcement/asx/b2acbafea79ac239216416f7e5149c6d |
Standard and Poor's Announcement
|
2024-09-12 18:55:00 |
Becoming a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/11e4a6110cf84c2fb0e667ecd87d28f3 |
Becoming a substantial holder
|
2024-09-16 08:30:00 |
New Positive Efficacy Data for Efti in Head and Neck Cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/b3cf6428a84d82cbe9fd27938def2980 |
|
2024-09-18 08:32:00 |
Data to be presented from Ph II trial in Soft Tissue Sarcoma |
0 |
https://app.sharelinktechnologies.com/announcement/asx/268871fa449ec5591e82e359e3fb83ac |
|
2024-09-19 09:55:00 |
Change of Director's Interest Notice - M Voigt |
0 |
https://app.sharelinktechnologies.com/announcement/asx/bc5e695552849b20005814f2d7cd7a43 |
Change of Director's Interest Notice
|
2024-09-24 08:29:00 |
Immutep receives A$3.6 million French R&D Tax Incentive |
1 |
https://app.sharelinktechnologies.com/announcement/asx/65e630625229a1cb56a832773d7bef29 |
|
2024-09-24 16:39:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/0c1d3aeca4e557938ad363d3fd17f259 |
Change in substantial holding
|
2024-09-25 15:29:00 |
Change in substantial holding from IFL |
0 |
https://app.sharelinktechnologies.com/announcement/asx/28ae92a0ab102c34464716789266900f |
Change in substantial holding
|
2024-09-26 19:00:00 |
Ceasing to be a substantial holder |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6997df248ad9307896de112c512c065d |
Ceasing to be a substantial holder
|
2024-10-01 12:42:00 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/f4464c6201e29bbdead03db73241e3dc |
Appendix 2A (Application for Quotation of Securities
|
2024-10-02 14:47:00 |
Change of Director's Interest Notice - Pete Meyers |
0 |
https://app.sharelinktechnologies.com/announcement/asx/92bd294e79e2513466f54ac8fa5549f0 |
Change of Director's Interest Notice
|
2024-10-03 09:50:00 |
Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed |
1 |
https://app.sharelinktechnologies.com/announcement/asx/7eac6a291d939a8c2cf3e45da7c101af |
|
2024-10-04 16:57:00 |
Resignation of Non-executive Director |
0 |
https://app.sharelinktechnologies.com/announcement/asx/ec93076537735b3cc04465e90c5b1603 |
Director Appointment/Resignation
|
2024-10-10 11:38:00 |
2024 AGM & Key Dates |
0 |
https://app.sharelinktechnologies.com/announcement/asx/950ab011da15330c28687616bd6a47b1 |
Notice of Meeting - Other
|